Last reviewed · How we verify
Linagliptin and Basal Insulin
Linagliptin inhibits dipeptidyl peptidase-4 (DPP-4) to increase incretin levels and improve glycemic control, while basal insulin provides long-acting glucose lowering.
Linagliptin inhibits dipeptidyl peptidase-4 (DPP-4) to increase incretin levels and improve glycemic control, while basal insulin provides long-acting glucose lowering. Used for Type 2 diabetes mellitus in patients inadequately controlled on other antidiabetic agents.
At a glance
| Generic name | Linagliptin and Basal Insulin |
|---|---|
| Also known as | Trajenta (Linagliptin) |
| Sponsor | Rabin Medical Center |
| Drug class | DPP-4 inhibitor combined with basal insulin |
| Target | DPP-4 (dipeptidyl peptidase-4) and insulin receptor |
| Modality | Small molecule |
| Therapeutic area | Diabetes |
| Phase | Phase 3 |
Mechanism of action
This combination therapy targets type 2 diabetes through two complementary mechanisms: linagliptin enhances the action of endogenous incretin hormones (GLP-1 and GIP) by blocking their degradation, thereby stimulating insulin secretion in a glucose-dependent manner. Basal insulin provides exogenous long-acting insulin to suppress hepatic glucose production and improve overall glycemic control. Together, they address both postprandial and fasting hyperglycemia.
Approved indications
- Type 2 diabetes mellitus in patients inadequately controlled on other antidiabetic agents
Common side effects
- Hypoglycemia
- Nasopharyngitis
- Headache
- Upper respiratory tract infection
Key clinical trials
- New Triple Therapy in Newly Diagnosed Type 2 Diabetes (PHASE3)
- Gliflozins and Cardiovascular Risk Factors in Type 2 Diabetes (GIOIA)
- Diabetes Study of Linagliptin and Empagliflozin in Children and Adolescents (DINAMO)TM (PHASE3)
- BESTMED: Observational Evaluation of Second Line Therapy Medications in Diabetes
- Research on Optimal Strategy of Hypoglycemic Therapy for Cirrhosis With Diabetes (PHASE3)
- Dipeptidyl Peptidase-4 Inhibitor (DPP4i) for the Control of Hyperglycemia in Patients With COVID-19 (PHASE3)
- A Comparison of Two Treatment Strategies in Older Participants With Type 2 Diabetes Mellitus (T2DM) (PHASE4)
- Linagliptin in Post-renal Transplantation
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Linagliptin and Basal Insulin CI brief — competitive landscape report
- Linagliptin and Basal Insulin updates RSS · CI watch RSS
- Rabin Medical Center portfolio CI